AxSpA-IBD: AxSpA Remission on TNFi Seen in Half of Patients AxSpA-IBD: AxSpA Remission on TNFi Seen in Half of Patients

Those who had had inflammatory bowel disease for less than 5 years and those taking adalimumab, as opposed to another TNFi, had higher likelihood of reaching axial spondyloarthritis remission.MDedge News
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Rheumatology News Source Type: news